Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation

[1]  I. Berindan‐Neagoe,et al.  An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes , 2020, Frontiers in Oncology.

[2]  X. Gu,et al.  Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Ling Zhang,et al.  Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing , 2020, Breast Cancer.

[4]  Dhanashree S. Kelkar,et al.  Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. , 2019, The Journal of clinical investigation.

[5]  R. Luque,et al.  Spliceosome Component SF3B1 as Novel Prognostic Biomarker and Therapeutic Target for Prostate Cancer. , 2019, Translational research : the journal of laboratory and clinical medicine.

[6]  Jianxiong Ji,et al.  RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation , 2019, Oncogene.

[7]  Hong Zhang,et al.  Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells , 2019, Artificial cells, nanomedicine, and biotechnology.

[8]  Shizhu Yu,et al.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B , 2019, The Journal of clinical investigation.

[9]  Shizhu Yu,et al.  Splicing factor SRSF 1 promotes gliomagenesis via oncogenic splice-switching of MYO 1 B , 2019 .

[10]  D. Bell,et al.  Molecular Genetics of Endometrial Carcinoma. , 2019, Annual review of pathology.

[11]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[12]  Steven J. M. Jones,et al.  Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.

[13]  Ping Zhu,et al.  Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.

[14]  Leng Han,et al.  A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. , 2017, Cell reports.

[15]  Robert E. Lewis,et al.  Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras , 2017, F1000Research.

[16]  Henning Urlaub,et al.  Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations. , 2016, Molecular cell.

[17]  C. Sette,et al.  Alternative splicing and cell survival: from tissue homeostasis to disease , 2016, Cell Death and Differentiation.

[18]  A. Krainer,et al.  Splicing-factor alterations in cancers , 2016, RNA.

[19]  N. Rosas-Murrieta,et al.  Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment , 2016, BioMed research international.

[20]  T. Saldi,et al.  Coupling of RNA Polymerase II Transcription Elongation with Pre-mRNA Splicing. , 2016, Journal of molecular biology.

[21]  Hai Huang,et al.  Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation , 2016, Oncotarget.

[22]  M. Mahfouz,et al.  CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B , 2016, Biochimie open.

[23]  S. Roman-Roman,et al.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage , 2016, Nature Communications.

[24]  Hsien-Da Huang,et al.  Genetic alterations in endometrial cancer by targeted next-generation sequencing. , 2016, Experimental and molecular pathology.

[25]  R. Bejar.  Splicing Factor Mutations in Cancer. , 2016, Advances in experimental medicine and biology.

[26]  Alexander V Penson,et al.  Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities , 2015, Proceedings of the National Academy of Sciences.

[27]  M Cazzola,et al.  Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2014, Leukemia.

[28]  M. Cazzola,et al.  Disruption of SF 3 B 1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2015 .

[29]  A. Althouse,et al.  USA endometrial cancer projections to 2030: should we be concerned? , 2014, Future oncology.

[30]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[31]  Ji-kai Wen,et al.  mRNA stability in the nucleus , 2014, Journal of Zhejiang University SCIENCE B.

[32]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[33]  T. Takayama,et al.  High antitumor activity of pladienolide B and its derivative in gastric cancer , 2013, Cancer science.

[34]  G. Mills,et al.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. , 2014, Cancer research.

[35]  David D. Anderson,et al.  Coherence between Cellular Responses and in Vitro Splicing Inhibition for the Anti-tumor Drug Pladienolide B and Its Analogs* , 2013, The Journal of Biological Chemistry.

[36]  Robert E. Lewis,et al.  Kinase Suppressor of Ras 2 (KSR2) Regulates Tumor Cell Transformation via AMPK , 2012, Molecular and Cellular Biology.

[37]  J. Maciejewski,et al.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders , 2012, Leukemia.

[38]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[39]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[40]  Y. Mizui,et al.  Biological validation that SF3b is a target of the antitumor macrolide pladienolide , 2011, The FEBS journal.

[41]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[42]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[43]  Nicholas C. Flytzanis,et al.  An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.

[44]  S. Ni,et al.  Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. , 2011, Cancer letters.

[45]  Eric S. Lander,et al.  SF 3 B 1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia , 2011 .

[46]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[47]  Zhenqiu Liu,et al.  Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer , 2010, Molecular Cancer.

[48]  T. Veenstra,et al.  KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. , 2009, Molecular cell.

[49]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[50]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[51]  U. Philippar,et al.  Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines , 2008, Clinical Cancer Research.

[52]  S. Dey,et al.  Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. , 2008, Cancer research.

[53]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[54]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[55]  M. Matsufuji,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. I. Taxonomy, fermentation, isolation and screening. , 2004, The Journal of antibiotics.

[56]  Y. Mizui,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation. , 2004, The Journal of antibiotics.

[57]  P. Goodfellow,et al.  PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. , 1998, Gynecologic oncology.

[58]  F. van Roy,et al.  Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. , 1998, Genomics.